Skip to Content
Stock Analyst Update

What Does New Pfizer CEO Appointment Signal?

We think that Albert Bourla will continue the wide-moat firm's current strategic focus.


Following  Pfizer's (PFE) announcement to name Albert Bourla the new CEO effective Jan. 1, 2019, we don't expect any changes to our $46 fair value estimate or wide moat rating. We continue to view the stock as modestly undervalued with the pipeline likely not fully appreciated by the investment community.

The announcement of Bourla's move to the top spot signals a likely continuation of Pfizer's strategic focus on moving toward areas of unmet medical need in drug development, divesting assets in areas lacking scale, and making synergistic midsize acquisitions, all of which should guide Pfizer to continued steady growth. Bourla's background as chief operating officer as well as leadership in the innovative drug business gives him strong credentials for running the overall organization. We believe his gaining the COO spot in January largely set him up for an eventual CEO appointment. This thoughtful and telegraphed passage of leadership is a welcome pathway and in contrast to the past CEO change at Pfizer, where Ian Read abruptly took over following increasing concerns about the previous CEO. While Bourla will probably want to leave his mark on Pfizer's legacy, we expect a calm hand at the helm similar to Read's, with decisions made in a calculated way in the best interest of shareholders and patients.

Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.

Damien Conover does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.